Management of Membranous Nephropathy in the PLA2R Era - PubMed (original) (raw)
Case Reports
. 2018 May 7;13(5):784-786.
doi: 10.2215/CJN.12461117. Epub 2018 Jan 29.
Affiliations
- PMID: 29378770
- PMCID: PMC5969486
- DOI: 10.2215/CJN.12461117
Case Reports
Management of Membranous Nephropathy in the PLA2R Era
Andrew S Bomback. Clin J Am Soc Nephrol. 2018.
No abstract available
Keywords: Antigen-Antibody Complex; Autoantibodies; Autoantigens; Biopsy; Epitopes; Glomerular Basement Membrane; Glomerulonephritis; Group IV Phospholipases A2; Humans; Membranous; PLA2R1 protein; Phospholipase A2; Phospholipases A2; Podocytes; Receptors; Thrombospondins; human; idiopathic nephrotic syndrome; membranous nephropathy.
Figures
Figure 1.
The use of serum antiphospholipase A2 receptor (anti-PLA2R) antibody testing and biopsy PLA2R antigen staining in the diagnosis and management of patients with membranous nephropathy (MN) is determined by the timing of such tests.
References
- Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J; GN-PROGRESS Study Group: Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70: 1510–1517, 2006 - PubMed
- Timmermans SA, Ayalon R, van Paassen P, Beck Jr. LH, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW; Limburg Renal Registry: Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis 62: 1223–1225, 2013 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources